Browse
Submit Data
Databases
API
Help

Dataset Information

24 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

A study of lapatinib in combination with oxaliplatin and capecitabine in oesophageal and gastric cancers

ABSTRACT: See https://www.cancerresearchuk.org/about-cancer/find-a-clinical-trial/a-trial-looking-lapatinib-with-chemotherapy-for-cancer-of-the-food-pipe-and-stomach-leo

DISEASE(S): Upper Gastro-intestinal Cancer Oesophagus,Oesophagogastric Adenocarcinoma,Stomach,Adenocarcinoma Of The Oesophagus,Gastric Cancer

PROVIDER: 2418700 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

ACCESS DATA

Json Xml

Similar Datasets

Alternative chemotherapy for frail or elderly patients with advanced gastric or oesophageal cancer

Project description:See http://www.cancerresearchuk.org/cancer-help/trials/a-trial-looking-at-chemotherapy-for-frail-or-elderly-patients-with-advanced-cancer-of-the-stomach-or-food-pipe-go2

| 2417793 | ecrin-mdr-crc

Minimally invasive oesophageal adenocarcinoma sentinel node biopsy 4.0

Project description:See http://cancerhelp.cancerresearchuk.org/trials/a-study-looking-finding-first-lymph-nodes-cancer-may-spread-people-having-surgery-cancer-food-pipe

| 2422556 | ecrin-mdr-crc

The BioStent study: Biodegradable oesophageal Stents plus radiotherapy in carcinoma of the oesophagus

Project description:See https://www.cancerresearchuk.org/about-cancer/find-a-clinical-trial/a-study-looking-at-biodegradable-stents-and-radiotherapy-for-cancer-of-the-oesophagus-biostent

| 2422285 | ecrin-mdr-crc

ATAC-seq of human oesophageal adenocarcinoma KYAE1 cell line treated with lapatinib

Project description:To investigate initial changes to chromatin accessibility associated with resistance to lapatinib, we performed ATAC-seq on KYAE1 cells treated with 500 nM lapatinib for 24 hours and vehicle control (DMSO) for 24 hours.

2022-09-26 | E-MTAB-10310 | biostudies-arrayexpress

ATAC-seq of human oesophageal adenocarcinoma OE19 cell line treated with lapatinib

Project description:To investigate changes to chromatin accessibility associated with resistance to lapatinib, we performed ATAC-seq on OE19 cells treated with 500 nM lapatinib for 1, 7 and 35 days and vehicle control (DMSO) for 1 day.

2022-09-26 | E-MTAB-10302 | biostudies-arrayexpress

RNA-seq of human oesophageal adenocarcinoma OE19 cell line treated with lapatinib

Project description:To investigate changes to gene expression associated with resistance to lapatinib, we performed ATAC-seq on OE19 cells treated with 500 nM lapatinib for 1, 7 and 35 days and vehicle control (DMSO) for 1 day.

2022-09-26 | E-MTAB-10304 | biostudies-arrayexpress

ATAC-seq of human oesophageal adenocarcinoma ESO26 cell line treated with lapatinib

Project description:To investigate initial changes to chromatin accessibility associated with resistance to lapatinib, we performed ATAC-seq on ESO26 cells treated with 500 nM lapatinib plus 1000 nM MK-2206 (an AKT inhibitor) for 24 hours and vehicle control (DMSO) for 24 hours.

2022-09-26 | E-MTAB-10307 | biostudies-arrayexpress

ATAC-seq of human oesophageal adenocarcinoma WTSI-OESO_009 (CAM408) organoid treated with lapatinib

Project description:To investigate initial changes to chromatin accessibility associated with resistance to lapatinib, we performed ATAC-seq on WTSI-OESO_009 cells treated with 1000 nM lapatinib for 24 hours and vehicle control (DMSO) for 24 hours.

2022-09-26 | E-MTAB-10306 | biostudies-arrayexpress

The role of faecal occult blood testing in identifying subjects with iron deficiency anaemia who have underlying gastro-intestinal cancer

Project description:See https://www.cancerresearchuk.org/about-cancer/find-a-clinical-trial/a-study-looking-whether-testing-poo-blood-can-show-who-might-be-at-risk-cancer-stomach-bowel

| 2413197 | ecrin-mdr-crc

ChIP-seq of PPARGC1A in oesophageal adenocarcinoma OE19 cells treated with lapatinib

Project description:ChIP-seq for PPARGC1A was performed in OE19 cells to identify genomic binding sites. Cells were treated with 500 nM lapatinib for 48 hours.

2022-09-26 | E-MTAB-11300 | biostudies-arrayexpress

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data